Improvements in Glycemic Outcomes in 4738 Children, Adolescents, and Adults with Type 1 Diabetes Initiating a Tubeless Insulin Management System
Open accessThe DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Despite recent advances in diabetes technology, most people living with type 1 diabetes mellitus (T1D) are unable to meet glycemic targets. Real-world evidence can provide insight into outcomes achieved with specific treatment devices when used in clinical practice. The aim of this study was to analyze real-world outcomes collected from a large cohort of people living with T1D and initiating treatment with the Omnipod DASH System. METHODS: In this retrospective observational study, real-world outcomes were analyzed from a database of information collected from people with T1D initiating the Omnipod DASH System. Information in the database was either taken directly from the patient's medical record or self-reported if medical records were unavailable. The primary outcome was change in glycated hemoglobin (HbA1c) from baseline (before initiation) to 3 months after initiation. Secondary outcomes were changes in total daily dose of insulin (TDD) and self-reported frequency of hypoglycemic events (< 70 mg/dL). Results are separated for the adult (≥ 18 years, N = 3341) and pediatric (< 18 years, N = 1397) cohorts. RESULTS: The change in HbA1c from baseline was - 0.9 ± 1.6% ( - 10 ± 18 mmol/mol; p < 0.0001) in adults and - 0.9 ± 2.0% ( - 10 ± 22 mmol/mol; p < 0.0001) in the pediatric cohort. For those previously using multiple daily injections, HbA1c decreased by - 1.0 ± 1.7% ( - 11 ± 19 mmol/mol) in adults and - 1.0 ± 2.1% ( - 11 ± 23 mmol/mol) in the pediatric cohort (both p < 0.0001). Hypoglycemic events decreased in adults from 2.9 to 1.3 episodes per week ( - 1.6 ± 3.2 events/week; p < 0.0001), and in the pediatric cohort from 2.8 to 1.5 episodes per week ( - 1.3 ± 2.7 events/week; p < 0.0001). In adults, TDD decreased by 19.9% (p < 0.0001), and it remained stable in the pediatric cohort (p > 0.05). CONCLUSIONS: Real-world outcomes from this large cohort of people initiating therapy with the Omnipod DASH System showed significant improvement in HbA1c and a substantial reduction in hypoglycemic events after 3 months of use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Real-world data on insulin pump use in individuals with type 1 diabetes show benefits in A1C levels and hypoglycemia reductions as well as total daily insulin dose reduction (164).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [164]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389 · cited 1×
“Of note is the emerging body of evidence highlighting the impact of T1D on those diagnosed at a young age, including an increased risk for cardiovascular disease [9], deteriorations in neurocognitive health [10, 11], and an overall decreased life span [12].”
BackgroundRawshani, A., Sattar, N., Franzén, S., Rawshani, A., Hattersley, A. T., Svensson, A.-M., Eliasson, B., & Gudbjörnsdottir, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31506-x · Cited by 802 · cited 1×
“Of note is the emerging body of evidence highlighting the impact of T1D on those diagnosed at a young age, including an increased risk for cardiovascular disease [9], deteriorations in neurocognitive health [10, 11], and an overall decreased life span [12].”
BackgroundGlucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring
Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., Brown, A. S., Heinemann, L., Aleppo, G., Ryan, D. B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1581 · Cited by 684
Self-citationTrends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001-2017
Lawrence, J. M., Divers, J., Isom, S., Saydah, S., Imperatore, G., Pihoker, C., Marcovina, S. M., Mayer-Davis, E. J., Hamman, R. F., Dolan, L., et al. (2021) · JAMA · doi:10.1001/jama.2021.11165 · Cited by 619
Pickup, J. C., & Sutton, A. J. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02486.x · Cited by 617
Pickup, J., Mattock, M., & Kerry, S. (2002) · BMJ · doi:10.1136/bmj.324.7339.705 · Cited by 483 · cited 1×
“These findings are in accordance with previous studies that report a significant reduction in TDD when switching to a tubeless pump from prior tubed pump or MDI therapy [29, 54, 55].”
Result
Research works printed but not linked: 1
- Carlson AL, Huyett LM, Jantz J, Chang A, Vienneau T, Ly TT. Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system. Diabetes Res Clin Pract. 2021;174:108735. · DOI · Paper page
Cited by
7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
Self-citation7. Diabetes Technology: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s007 · Cited by 281
Self-citation7. Diabetes Technology: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s007 · Cited by 279
Forlenza, G. P., DeSalvo, D. J., Aleppo, G., Wilmot, E. G., Berget, C., Huyett, L. M., Hadjiyianni, I., Méndez, J. J., Conroy, L. R., Ly, T. T., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0578 · Cited by 99
“41 The use of the lowest average glucose target (110mg/dL) with the Omnipod 5 System led to further glycemic improvements for prior Omnipod DASH and CGM users under real-world conditions.”
Self-citationReal-World Evidence Analysis of a Hybrid Closed-Loop System
Alwan, H., Wilinska, M. E., Ruan, Y., Silva, J. D., & Hovorka, R. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231185348 · Cited by 43
“16 To our knowledge, this is the first RWE analysis of data of a hybrid closed-loop system that includes very young children ( ≤ 6 years old).”
Metadata
- Authors
- Aleppo, G., DeSalvo, D. J., Lauand, F., Huyett, L. M., Chang, A., Vienneau, T., & Ly, T. T.
- Affiliations
- Northwestern University (US)
- Baylor College of Medicine (US)
- Insulet (United States) (US)
- Corresponding author
- Huyett, Lauren M.
- Venue
- Diabetes Therapy
- Published
- 2023-02-10
- Volume
- 14
- Issue
- 3
- Pages
- 593-610
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC9913031
- OpenAlex
- W4319812787
- Cited by
- 19
- References
- 60
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 5 · 2023: 2
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Insulet Corporation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, HbA1c, glycemic control, hypoglycemia, total daily insulin dose, insulin pump therapy, multiple daily insulin injections, real-world outcomes, children and adolescents, adults, diabetes technology adoption
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improvements in Glycemic Outcomes in 4738 Children, Adolescents, and Adults with Type 1 Diabetes Initiating a Tubeless Insulin Management System. https://app.cochat.ai/papers/10.1007/s13300-023-01366-9
- The paper
- Aleppo, G., DeSalvo, D. J., Lauand, F., Huyett, L. M., Chang, A., Vienneau, T., & Ly, T. T. (2023). Improvements in Glycemic Outcomes in 4738 Children, Adolescents, and Adults with Type 1 Diabetes Initiating a Tubeless Insulin Management System. Diabetes Therapy. https://doi.org/10.1007/s13300-023-01366-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.